Barclays Initiates Coverage on Cooper Companies (NASDAQ:COO)

Key Points

• Barclays has initiated coverage on Cooper Companies (NASDAQ:COO) with an "overweight" rating and a price target of $85.00, indicating a potential upside of 22.66% from the current price.
• The company reported $1.10 EPS for the last quarter, exceeding analysts' consensus expectations, and provided guidance for Q4 2025 of 1.100-1.140 EPS.
• Cooper Companies announced a stock buyback plan allowing the company to repurchase $2.00 billion worth of shares, representing up to 15.4% of its outstanding stock, suggesting the board believes its shares are undervalued.

Equities research analysts at Barclays assumed coverage on shares of Cooper Companies (NASDAQ:COO - Get Free Report) in a research note issued on Monday, MarketBeat Ratings reports. The firm set an "overweight" rating and a $85.00 price target on the medical device company's stock. Barclays's target price suggests a potential upside of 22.66% from the company's current price.

A number of other research firms also recently commented on COO. Needham & Company LLC reissued a "buy" rating and set a $94.00 price objective on shares of Cooper Companies in a report on Thursday, August 28th. JPMorgan Chase & Co. decreased their price objective on shares of Cooper Companies from $76.00 to $66.00 and set a "neutral" rating on the stock in a report on Thursday, August 28th. Morgan Stanley set a $76.00 price target on shares of Cooper Companies and gave the company an "equal weight" rating in a report on Thursday, August 28th. BNP Paribas raised shares of Cooper Companies from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 22nd. Finally, BNP Paribas Exane raised shares of Cooper Companies from a "neutral" rating to an "outperform" rating and set a $92.00 price target on the stock in a report on Tuesday, July 22nd. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $84.77.

Cooper Companies Stock Up 1.4%

COO stock opened at $69.30 on Monday. The company has a market cap of $13.78 billion, a P/E ratio of 34.14, a P/E/G ratio of 1.79 and a beta of 1.02. Cooper Companies has a 52 week low of $61.78 and a 52 week high of $109.37. The company's 50-day moving average price is $69.39 and its 200 day moving average price is $73.48. The company has a current ratio of 2.12, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings data on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, topping analysts' consensus estimates of $1.07 by $0.03. The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The firm's revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. On average, research analysts expect that Cooper Companies will post 3.98 earnings per share for the current fiscal year.

Cooper Companies declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, September 17th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical device company to reacquire up to 15.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board believes its stock is undervalued.

Insider Buying and Selling at Cooper Companies

In other news, EVP Brian G. Andrews acquired 1,525 shares of Cooper Companies stock in a transaction that occurred on Tuesday, September 2nd. The shares were acquired at an average price of $65.68 per share, with a total value of $100,162.00. Following the completion of the purchase, the executive vice president owned 22,191 shares of the company's stock, valued at approximately $1,457,504.88. This represents a 7.38% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Daniel G. Mcbride acquired 3,000 shares of Cooper Companies stock in a transaction that occurred on Tuesday, September 2nd. The shares were purchased at an average cost of $65.04 per share, for a total transaction of $195,120.00. Following the purchase, the chief operating officer directly owned 63,120 shares of the company's stock, valued at approximately $4,105,324.80. This trade represents a 4.99% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 17,975 shares of company stock valued at $1,216,346. 1.98% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Cooper Companies

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Cooper Companies by 1.8% during the second quarter. Vanguard Group Inc. now owns 24,254,677 shares of the medical device company's stock valued at $1,725,963,000 after buying an additional 421,423 shares during the period. State Street Corp increased its position in Cooper Companies by 1.2% during the second quarter. State Street Corp now owns 8,659,741 shares of the medical device company's stock worth $616,227,000 after purchasing an additional 104,910 shares during the last quarter. Geode Capital Management LLC increased its position in Cooper Companies by 2.5% during the second quarter. Geode Capital Management LLC now owns 5,205,615 shares of the medical device company's stock worth $368,893,000 after purchasing an additional 127,907 shares during the last quarter. JPMorgan Chase & Co. increased its position in Cooper Companies by 3.4% during the first quarter. JPMorgan Chase & Co. now owns 5,177,008 shares of the medical device company's stock worth $436,681,000 after purchasing an additional 172,485 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in Cooper Companies by 17.0% during the first quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company's stock worth $399,340,000 after purchasing an additional 686,751 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company's stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.